Articles by Felicia Forma, BSc
The Cost of Adherence Mismeasurement in Serious Mental Illness: A Claims-Based Analysis
ByJason Shafrin, PhD,Felicia Forma, BSc,Ethan Scherer, PhD,Ainslie Hatch, PhD,Edward Vytlacil, PhD,Darius Lakdawalla, PhD This study demonstrates that common pharmacy claims-based measures underestimate the effect of actual adherence on inpatient costs among patients with serious mental illness.
Improving Patient-Centered Care in Diabetes With Comparative Effectiveness Research
ByDouglas K. Owens, MD,Wade Aubry, MD,Roy Beck, MD,Joshua Benner, MD,Jan E. Berger, PharmD,Michael E. Chernew, PhD,Felicia Forma, BSc,Dana P. Goldman, PhD,William H. Herman, MD,Rebecca Killion, MA,Darius Lakdawalla, PhD,Anne L Peters, MD Comparative Effectiveness Research and Formulary Placement: The Case of Diabetes
ByMichael E. Chernew, PhD,Rick McKellar, BS,Wade Aubry, MD,Roy Beck, MD, PhD,Joshua Benner, PharmD, ScD,Jan E. Berger, MD, MJ,A. Mark Fendrick, MD,Felicia Forma, BSc,Dana Goldman, PhD,Anne Peters, MD,Rebecca Killion, MA,Darius Lakdawalla, PhD,Douglas K. Owens, MD,Joe Stahl, MA Comparative Effectiveness Research and Formulary Placement: The Case of Diabetes
ByMichael E. Chernew, PhD,Rick McKellar, BS,Wade Aubry, MD,Roy Beck, MD, PhD,Joshua Benner, PharmD, ScD,Jan E. Berger, MD, MJ,A. Mark Fendrick, MD,Felicia Forma, BSc,Dana Goldman, PhD,Anne Peters, MD,Rebecca Killion, MA,Darius Lakdawalla, PhD,Douglas K. Owens, MD,Joe Stahl, MA Formularies of the future should use evidence-produced CER to better target, not limit, diabetes care.
Cost Sharing, Adherence, and Health Outcomes in Patients With Diabetes
ByTeresa B. Gibson, PhD,Xue Song, PhD,Berhanu Alemayehu, DrPH,Sara S. Wang, PhD,Jessica L. Waddell, MPH,Jonathan R. Bouchard, MS, RPh,Felicia Forma, BSc Higher cost-sharing levels reduced adherence to antidiabetic medications in patients with type 2 diabetes.